Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PLRX save search
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2023-02-07 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
therapeutics
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Published: 2023-02-02 (Crawled : 13:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -0.3%
H: 2.42%
C: -1.93%
pln-1010 treatment fda clearance drug for therapeutics tumors
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Published: 2023-01-27 (Crawled : 22:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
JNJ | News | $163.61 0.13% 0.24% 4.7M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 4.99%
H: 0.0%
C: 0.0%
therapeutics
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
Published: 2023-01-25 (Crawled : 03:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 4.99%
H: 0.0%
C: 0.0%
offering therapeutics
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 58.7%
H: 4.17%
C: -13.58%
fibrosis trial therapeutics positive phase 2b
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -1.72%
H: 3.29%
C: 3.02%
pln-7480 treatment fibrosis designation for therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2022-11-15 (Crawled : 13:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 3.37%
H: 5.71%
C: 3.14%
therapeutics
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
Published: 2022-09-15 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -1.4%
H: 0.96%
C: -0.04%
therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 1.76%
H: 4.84%
C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
Published: 2022-08-02 (Crawled : 14:20) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
conference therapeutics
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
Published: 2022-07-21 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 0.41%
H: 0.7%
C: -1.62%
pln-7480 treatment fda designation for therapeutics
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
Published: 2022-07-12 (Crawled : 00:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -9.7%
H: 2.86%
C: -6.07%
offering therapeutics
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Published: 2022-07-10 (Crawled : 00:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 85.19%
H: 43.66%
C: 43.66%
pln-7480 fibrosis trial therapeutics positive phase 2b
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
Published: 2022-06-24 (Crawled : 12:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 6.35%
H: 12.77%
C: -2.39%
preclinical trial therapeutics pre-clinical phase 2b
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
Published: 2022-06-22 (Crawled : 13:20) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
| Email alert
Add to watchlist
treatment preclinical for therapeutics pre-clinical
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
Published: 2022-06-16 (Crawled : 13:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -4.74%
H: 3.7%
C: 2.56%
fibrosis collaboration therapeutics
Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
Published: 2022-05-18 (Crawled : 15:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -3.25%
H: 8.19%
C: 1.68%
conference therapeutics international
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-05-03 (Crawled : 13:20) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 0.88%
H: 2.62%
C: -5.26%
pln-7480 treatment fda fibrosis designation therapeutics fast track designation
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
Published: 2022-05-02 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -0.85%
H: 6.37%
C: -2.75%
conference therapeutics international
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CZOO | $0.2001 -16.63% 1874.01% 3.3M
|
AVRO | $1.69 93.7% 54.08% 38M
|
Health Technology
CELZ | $1.04 101.04% 50.26% 140M
|
WETG | $0.65 58.54% 37.88% 27M
|
GFAI | $0.5408 58.36% 36.88% 89M
|
KPRX | $6.94 52.53% 34.15% 36M
|
Manufacturing
PRFX | $0.7236 44.72% 30.07% 14M
|
Health Technology
BJDX | $0.64 37.16% 23.51% 2.8M
|
SOUN 4 | $4.63 28.61% 22.08% 62M
|
THCH | News | $5.3 26.19% 19.69% 750K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.